electroCore, Inc. (NASDAQ:ECOR - Free Report) - Investment analysts at Brookline Capital Management lowered their FY2024 EPS estimates for electroCore in a note issued to investors on Thursday, November 14th. Brookline Capital Management analyst T. Bussian now expects that the company will earn ($1.40) per share for the year, down from their prior forecast of ($1.03). The consensus estimate for electroCore's current full-year earnings is ($1.44) per share. Brookline Capital Management also issued estimates for electroCore's Q4 2024 earnings at ($0.33) EPS.
electroCore Price Performance
NASDAQ ECOR traded down $1.29 during trading hours on Monday, hitting $9.65. 262,229 shares of the company's stock traded hands, compared to its average volume of 27,908. The company has a market capitalization of $63.26 million, a PE ratio of -5.27 and a beta of 0.56. The firm's 50-day moving average is $8.96 and its 200-day moving average is $7.26. electroCore has a 52-week low of $5.02 and a 52-week high of $14.20.
Hedge Funds Weigh In On electroCore
A number of institutional investors have recently added to or reduced their stakes in ECOR. International Assets Investment Management LLC boosted its holdings in electroCore by 689.1% in the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company's stock valued at $3,864,000 after purchasing an additional 467,326 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of electroCore by 3.4% during the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company's stock worth $442,000 after purchasing an additional 2,270 shares during the last quarter. Geode Capital Management LLC raised its holdings in electroCore by 10.3% in the 3rd quarter. Geode Capital Management LLC now owns 63,485 shares of the company's stock valued at $458,000 after buying an additional 5,951 shares during the period. Finally, HighTower Advisors LLC acquired a new position in electroCore in the third quarter valued at about $255,000. Hedge funds and other institutional investors own 26.74% of the company's stock.
About electroCore
(
Get Free Report)
electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
See Also
Before you consider electroCore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and electroCore wasn't on the list.
While electroCore currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
